Paratek's Stock Gains After Nuzyra's Oral Regime Wins FDA Approval For Pneumonia

The FDA has approved Paratek Pharmaceuticals Inc's PRTK supplemental marketing application for the oral-only dosing regimen of Nuzyra for Community-Acquired Bacterial Pneumonia (CABP).
The approval of an oral-only dose regimen for NUZYRA represents a significant opportunity to treat patients in either the outpatient or primary care setting to potentially reduces/eliminates hospitalizations and the associated risk and costs from a hospital stay, the company said.
The FDA approved Nuzyra in 2018 as an antibiotic with both once-daily oral and intravenous formulations to treat CABP and acute bacterial skin and skin structure infections.
Price Action: PRTK shares are up 7.6% at $8.84 during the market session on the last check Tuesday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.